Etelcalcetide Phase 3 Pediatric Trial Recruiting as of Aug 21, 2026

On August 21, 2026, a trial status update was recorded for a Phase 3 study of etelcalcetide. The trial, registered as NCT03969329, is titled "A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis." Its current status is listed as recruiting. The study is designed to evaluate etelcalcetide in a pediatric population diagnosed with secondary hyperparathyroidism who are undergoing hemodialysis. Etelcalcetide itself is an approved compound, and this Phase 3 trial represents ongoing clinical research into its use in a younger patient group receiving dialysis treatment. No outcomes, efficacy data, or safety results have been reported as part of this update. The listing reflects only the recruitment status and trial phase as of the date noted. Additional details about eligibility, trial design, and enrollment can be found through the official clinical trial registry entry. This update does not indicate whether the study has produced any findings, as it remains in the recruiting stage. For more background on etelcalcetide, including its approved uses and general information, readers can consult the compound overview.